Get started

Stockpicks

SoFi to Become Publicly-traded via Merger with IPOESoFi, A Leading Next-Generation Financial Services Platform, to Become Publicly-traded via Merger with Social Capital Hedosophia SoFi’s mission is to help people achieve financial independence by getting their money right, providing access to a comprehensive suite of services in a single app that empowers members to borrow, save, spend, invest and protect their money SoFi’s one-stop shop, multi-product strategy and leading technology platform, Galileo, place the company at the epicenter of the digital revolution in financial services Transaction values SoFi at an equity value of $8.65 billion post-money and is expected to provide up to $2.4 billion in cash proceeds, including a fully committed PIPE of $1.2 billion, and up to $805 million of cash held in the trust account of Social Capital Hedosophia Holdings Corp. V (“SCH”), in addition to a previous anchor investment from funds and accounts advised by T. Rowe Price Associates, Inc. that closed on December 30, 2020 The PIPE is being led by Chamath Palihapitiya, Founder and CEO of SCH, and Hedosophia, who are together contributing $275 million; top-tier institutional investors comprise the remaining $950 million of the PIPE, including funds and accounts managed by BlackRock, Altimeter Capital Management, Baron Capital Group, Coatue Management, Durable Capital Partners LP, and Healthcare of Ontario Pension Plan (HOOPP) SoFi delivered over $200 million in total net revenue in the third quarter of 2020 and is on track to generate approximately $1 billion of estimated adjusted net revenue in 2021, representing year-over-year growth of approximately 60 percent, and full-year adjusted EBITDA profitability. Transaction expected to close in the first quarter of 2021. www.businesswire.com
I
by AlenCiken
$ENG PT 18 and $OEG PT 9-11 Solar farms for $AMZN$ENG PT 18 and higher FuelCell Energy, Inc., together with its subsidiaries, designs, manufactures, sells, installs, operates, and services stationary fuel cell power plants for distributed power generation. The company offers SureSource product line based on carbonate fuel cell technology in various configurations, including on-site power, utility grid support, distributed hydrogen, and micro-grid, as well as multi-megawatt applications; and SureSource Recovery power plants for natural gas pipeline applications. It also provides SureSource Capture system that separates carbon dioxide from the flue gases of natural gas, biomass, or coal-fired power plants, as well as industrial facilities; and SOFC/SOEC and Energy Storage, a solution for energy storage using solid oxide technology. The company's SureSource power plants generate electricity and usable heat. It serves various markets, such as utilities and independent power producers, industrial and process applications, education and health care, data centers and communication, wastewater treatment, government, and commercial and hospitality. The company primarily operates in the United States, South Korea, England, and Germany. FuelCell Energy, Inc. was founded in 1969 and is headquartered in Danbury, Connecticut. $OEG PT 9-11 and higher Orbital Energy Group, Inc. engages in the design, installation, and commissioning of industrial gas sampling, measurement, and delivery systems for energy, power, and processing markets in the United States and the United Kingdom. It also provides engineering, construction, maintenance, and emergency response solutions to the power, utilities, and midstream markets; and engineering, procurement, and construction services in the renewable energy industry The company, formerly known as CUI Global, Inc., was founded in 1998 and is based in Houston, Texas.
OLong
by BADQOMOCAWGOWLD
1
ISR has received FDA 510(k) clearanceC4 Imaging Announces Sirius Positive Signal MRI Marker Given FDA 510(k) Clearance for Use with Isoray’s Cesium-131 Brachytherapy Seeds to Treat Prostate Cancer ISR has received FDA 510(k) clearance for the use of C4 Imaging’s Sirius® positive-signal MRI (Magnetic Resonance Imaging) Markers with Isoray’s Cesium-131, brachytherapy seeds. Sirius MRI Markers will enable Isoray’s customers to fully utilize the benefits of MRI seed localization. Brachytherapy, or internal radiation therapy, is a leading, cost-effective option for the treatment of prostate cancer. Isoray is the world’s only producer of Cesium-131, commercially known as Cesium Blu™, brachytherapy seeds. Cesium-131 is a radioactive isotope that delivers a minimally invasive and highly targeted treatment to the site of the cancer preserving healthy tissue and organs. Patients benefit from the rapid resolution of their side effects allowing them to return to their normal lives quickly. finance.yahoo.com
I
by AlenCiken
2
“Strong Buy” Penny Stock That Could Deliver Massive Returnis engaged in the development of gene therapies for rare, frequently terminal, diseases, including neurometabolic disorders, primary immune deficiencies, and blood disorders. The gene therapy approach uses blood stem cells to deliver corrected genetic information directly into the patient’s body. Orchard’s pipeline demonstrates the diversity of disorders amenable to gene therapy – the company has no less than 12 drug candidates in development. Among these candidates, Libmeldy (OTL-200) stands out. Libmeldy is in commercialization stages as a treatment for MLD (metachromatic leukodystrophy), a rare, mutation-based genetic disorder of the nervous system, received its approval for medical use in the EU in December 2020. “We look forward to the company’s commercial execution in the EU and an eventual 2022 approval in the US. Last month ORTX received IND clearance from the FDA for the program paving the way for discussions with the US regulators to decide a suitable path forward toward a BLA filing.” with possibly two gene therapies approved in the next 12-18 months and a pivotal study beginning in a third (MPS-I), we think ORTX shares are undervalued at these levels," the analyst concluded. Wedbush analyst David Nierengarten rates ORTX as Outperform (i.e. Buy), and his $15 price target indicates a potential for 241% growth in the year ahead. Only Buy ratings, 3, in fact, have been issued in the last three months. Therefore, ORTX gets a Strong Buy consensus rating. At $15, the average price target indicates shares could appreciate by 241% in the year ahead. finance.yahoo.com
O
by AlenCiken
Is Facebook losing friends?Facebook has been a holding in the portfolio since late November but has been a slow moving loser. The low end of the weekly range (rectangle low 264) was tested today but price responded well. I have been looking for all-time highs but its recent performance has given me doubts. For now we just sit and wait. The company is definitely not getting the love it once did but that can change at anytime. Todays low will be the line in the sand. Below todays low we will cut the position and re-evaluate
NASDAQ:META
by IngenuityTrading
1
$ZOM entry PT .40 PT .90 and higherZomedica Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. Its lead drug product candidate is ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies. The company is also developing ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. It has a collaboration agreement with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
AMEX:ZOMLong
by BADQOMOCAWGOWLD
1
Hoping Li can regain its spark #stocksLi is current reversal play in the portfolio with a stop below 26. After a brief exit to the downside from the near term range (rectangle box), the stock has reversed back up into the range. I am playing for a further breakout above 35. The stock is very volatile so I am giving it room. Todays down move and anywhere between here and the 27 area are still buying opportunities as long as the reversal structure stays intact and we can get some positive rate of change.
NASDAQ:LILong
by IngenuityTrading
Stay in autopilot or hit the brakes?Tesla's run has been nothing but extraordinary but as always in trading the question is what is next. The two trendlines are just the 3 and 4 standard deviation regression lines from the range breakout from November. If you are in the stock you could take some profits below those lines but that does not mean to short the stock. The near term range low zone is 655 to 614. Above those levels the trend is still up but if tesla closes below that area with any significance then the trend would be more bearish. This expansion breakout out of the longer term range has been strong and the stock may feel "overvalued" but don't trade on feelings. For now lets wait to see how price reacts to the regression lines and then the near term range low before we make any decisions Ranges- are identified by the white boxes. Will always be classified by a swing high and low on either a monthly or weekly basis
NASDAQ:TSLA
by IngenuityTrading
The9 to Start the Cryptocurrencies BusinessThe9 Signed a Legally Binding Cooperation and Investment Term Sheet with Cryptocurrencies Mining Investors Led by Jianping Kong to Start the Cryptocurrencies Business The9 has begun to deploy its blockchain and cryptocurrencies business strategy. This time, we are cooperating with investors including Mr. Jianping Kong. They have rich experience and resources in the field of cryptocurrencies mining machine manufacturing and cryptocurrencies mining operation and should be able to assist The9 to launch our cryptocurrencies mining operation. Our goal is to build up cryptocurrencies mining machines for The9 that will contribute 8% to 10% of the global hash rate of Bitcoin, 10% of the global hash rate of Ethereum and 10% of the global hash rate of Grin and become one of the world's largest cryptocurrencies mining companies in terms of hash rate. This will also speed up our other cryptocurrency related businesses. It has been 12 years since the birth of Bitcoin. Pursuant to the Term Sheet, The9 will issue Class A ordinary shares and warrants to the Investors. The9 is expected to receive proceeds from the transactions contemplated under the Term Sheet in accordance with certain pre-agreed conditions, if realized. The Investors are expected to utilize their cryptocurrencies mining industry resources to assist The9 for its development of cryptocurrencies mining business. The9 will set up a new wholly owned subsidiary NBTC Limited to operate its blockchain and cryptocurrencies business. The9 will issue 8,108,100 Class A ordinary shares (equivalent to 270,270 ADSs) at US$0.1233 per Class A ordinary share (equivalent to US$3.7 per ADS) and 207,891,900 warrants, each warrant representing the right to purchase one Class A Ordinary share (equivalent to 6,929,730 ADSs assuming full exercise of warrants) to the Investors. The warrants will be divided into four equal tranches: - The exercise price of three tranches of warrants is US$0.1233 per Class A ordinary share (equivalent to US$3.7 per ADS) - The exercise price of the other tranche of warrants is US$0.2667 per Class A ordinary share (equivalent to US$8 per ADS). Each tranche of the warrants is subject to its vesting conditions including market capitalization of The9 reaching US$100 million, US$300 million, US$500 million and US$1 billion within the timeframes of 6 months, 12 months, 24 months and 36 months, respectively. If the Investors exercise all of the warrants, The9 is expected to raise an aggregate consideration of approximately US$34 million in this transaction from the Class A ordinary shares issuance consideration and warrants exercise. The9 has the right to decide whether the Investors shall make payments in the form of U.S. dollars or cryptocurrencies (including Bitcoin) in the definitive agreement. finance.yahoo.com
NASDAQ:NCTYLong
by AlenCiken
Line in the sand #stocksDJIA is testing its recent weekly low. This is an important level because a close below 29956 could mean a further move down into the breakout rectangle support zone from 29530 - 28328. For now the trend is still up despite the heavy selling today but lets keep an eye out for how the market closes today. Volatility is up but not near the highs of December and it seems to be moving much more then the overall market. We don't want to panic sell into the lows but we should remain cautious.
CBOT_MINI:YM1!
by IngenuityTrading
The $115+ NNOX Target + Patterns$NNOX is one of those volatile stocks that took the world by storm. If you don't like volatility, it is likely best to stay away from biotech or healthcare. That said, there are alot of expected catalysts. $NNOX have been heavily shortened, and it is in the opinion of many that lots of market manipulation has been and is going on. The short interest is low and the borrow rate is high. Currently as I see it, the pattern is still incrementally upwards. Nanox has the catalyst of factory announcements, FDA approvals for both single and multisource, plus the commencement of "device leasing". Currently with 4 catalyst, three of them that are expected to be big, a target of $115 seems reasonable. Support levels should be picking up soon, and unless one wants to flip for few cents or dollars per share as profit, this currently seems much better suited for a long term position. That said, I am long. Everything I say is on an opinion based basis. Please do your own due diligence and proceed with caution. Opinions mentioned here aren't meant to warrant solicited financial advice.
NASDAQ:NNOXLong
by gamer456148